Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Opdivo | nivolumab | Esophageal or gastroesophageal junction cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | nivolumab | Gastroesophageal junction or esophageal adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | nivolumab | Resectable Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Metastatic non small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Metastatic Renal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | nivolumab | Stage IIB or IIC melanoma, adjuvant | Active | |||
Opdivo & Yervoy in combo | Nivolumab & Ipilimumab in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo in combination with Yervoy | Nivolumab in combination with Ipilimumab | Advanced or Metastatic Renal Cell Carcinoma (RCC). | Reimburse with clinical criteria and/or conditions | Complete |